News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AlphaCore Pharma Reports Positive Phase 1 Results for ACP-501 (rhLCAT) in Patients With Stable Atherosclerosis


10/9/2012 9:34:58 AM

ANN ARBOR, Mich.--(BUSINESS WIRE)--AlphaCore Pharma, announced today that results from the company’s Phase 1 clinical trial have met the primary endpoint by demonstrating the safety and tolerability of the drug ACP-501 (recombinant human LCAT).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES